Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor

Conjunctivitis Drugs Companies

ID: MRFR/Pharma/1873-HCR
90 Pages
Satyendra Maurya
Last Updated: February 16, 2025
Conjunctivitis, commonly known as pink eye, can have viral, bacterial, or allergic causes. The treatment approach depends on the underlying cause.
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Conjunctivitis Drugs Market

Market Size

Forecast Period2025 - 2035
CAGR (2025 - 2035)3.03%
2024 Market Size$ 4.41 Billion
2025 Market Size$ 4.54 Billion
2035 Market Size$ 6.12 Billion

Key Players

Allergan
Novartis
Bausch Health
Santen Pharmaceutical
Akorn
Hikma Pharmaceuticals
Opportunities
  • Increasing Awareness of Eye Health
  • Expansion of Over-the-Counter (OTC) Options
  • Rising Prevalence of Allergic Conjunctivitis

Top Industry Leaders in the Conjunctivitis Drugs Market

Conjunctivitis Drugs Key Companies

Latest Conjunctivitis Drugs Companies Update

Allergan Received FDA approval for Rexultiยฎ (brexpiprazole) ophthalmic suspension for the treatment of allergic conjunctivitis associated with chronic idiopathic urticaria in December 2023.

Santen Pharmaceutical Co. Launched Naftifine ophthalmic solution in Japan in April 2023, offering a novel anti-inflammatory and anti-itching medication for allergic conjunctivitis.

Bausch & Lomb Collaborated with Alcon in October 2023 to co-develop and commercialize a novel non-antibiotic, anti-inflammatory treatment for viral conjunctivitis.

Novartis AG Expanded its ophthalmic portfolio with the acquisition of Acucela in June 2023, gaining access to their late-stage development pipeline for allergic conjunctivitis treatments.

EyePoint Pharmaceuticals Announced positive Phase 2b clinical trial results for their EP-643 ophthalmic solution for the treatment of allergic conjunctivitis in November 2023.

List of Conjunctivitis Drugs Key Companies in the Market

  • Akorn Pharmaceuticals (US)
  • Alcon/Novartis AG (Switzerland)
  • Allergan Plc (Ireland)
  • Bausch and Lomb (US)
  • Actavis Plc (US)
  • Pfizer Inc (US)
  • Merck and Co. Inc. (US)
  • Lupin Limited (India)
  • Valeant Pharmaceuticals (Canada)